Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BCAL Diagnostics Limited ( (AU:BDX) ) is now available.
BCAL Diagnostics Limited has announced a strategic partnership with Cancer Care Associates to accelerate the adoption of their non-invasive breast cancer diagnostic test, BREASTEST plus™. This partnership is a significant commercial milestone for BCAL, providing a pathway to market adoption and patient access through a leading oncology network in Australia. The collaboration is expected to generate revenue starting in FY2026 and strengthen BCAL’s commercial rollout strategy, potentially leading to broader national and international partnerships. The integration of BREASTEST plus™ into Cancer Care Associates’ offerings will support uptake in various settings and enhance BCAL’s data collection efforts, aiding discussions around reimbursement and regulatory approvals.
More about BCAL Diagnostics Limited
BCAL Diagnostics is an Australian and US-based biotechnology company focused on advancing early and accurate breast cancer detection. They offer innovative, non-invasive blood tests, such as the BREASTEST range, designed to complement existing breast screening methods and provide additional insights to rule out breast cancer. Founded in 2010 and headquartered in Sydney, BCAL is listed on the Australian Securities Exchange.
Average Trading Volume: 184,141
Technical Sentiment Signal: Sell
Current Market Cap: A$24.52M
See more insights into BDX stock on TipRanks’ Stock Analysis page.